Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysosomal acid glucosylceramidase (GCase), encoded by the GBA1 gene, is a lysosomal enzyme responsible for the hydrolysis of glucocerebroside into glucose and ceramide. It plays a crucial role in sphingolipid metabolism and cellular membrane turnover. Mutations in GBA1 lead to Gaucher disease, a lysosomal storage disorder. GBA1 variants are also associated with an increased risk of Parkinson's disease.
Enzyme replacement therapy (for Gaucher Disease); Chaperone therapy (for Gaucher Disease)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysosomal acid glucosylceramidase (GCase).